Abiramed 500 Tablet contains Abiraterone 500mg, a potent anti-androgen indicated for the treatment of metastatic castration-resistant prostate cancer. It helps in blocking androgen production, slowing tumor progression, and improving patient survival outcomes.
Abiraterone works by selectively inhibiting CYP17, an enzyme critical in androgen biosynthesis, thereby reducing testosterone levels and controlling prostate cancer growth. This targeted mechanism ensures effective therapeutic management in advanced stages of the disease.
Tablet formulation ensures accurate dosing, high bioavailability, and convenient administration for adult patients. Its clinical reliability and increasing adoption in oncology practices make it a high-demand product in the cancer care segment.
Adding Abiramed 500 Tablet to your oncology and anti-androgen portfolio strengthens your offerings with a trusted, fast-moving therapy. Its strong prescriber preference, hospital and clinic usage, and export potential make it ideal for PCD pharma companies, distributors, and third-party manufacturing partners.